| Year |
Citation |
Score |
| 2023 |
Jacobs MR, Olivero JE, Ok Choi H, Liao CP, Kashemirov BA, Katz JE, Gross ME, McKenna CE. Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration. Bioorganic & Medicinal Chemistry. 92: 117425. PMID 37544256 DOI: 10.1016/j.bmc.2023.117425 |
0.326 |
|
| 2020 |
Gross ME, Agus DB, Dorff TB, Pinski JK, Quinn DI, Castellanos O, Gilmore P, Shih JC. Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 32123315 DOI: 10.1038/s41391-020-0211-9 |
0.39 |
|
| 2019 |
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. PMID 31227432 DOI: 10.1016/J.Clgc.2019.02.010 |
0.376 |
|
| 2019 |
Gaur S, Gross ME, Liao CP, Qian B, Shih JC. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. The Prostate. PMID 30693539 DOI: 10.1002/Pros.23774 |
0.433 |
|
| 2018 |
Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross ME, Shih JC. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. PMID 29844571 DOI: 10.1038/S41388-018-0325-X |
0.339 |
|
| 2018 |
Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. International Journal of Cancer. PMID 29574703 DOI: 10.1002/ijc.31397 |
0.306 |
|
| 2017 |
Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clinical Genitourinary Cancer. PMID 28826933 DOI: 10.1016/j.clgc.2017.07.003 |
0.323 |
|
| 2017 |
Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocrine-Related Cancer. 24: 157-170. PMID 28264911 DOI: 10.1530/Erc-16-0138 |
0.438 |
|
| 2016 |
Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients Prostate Cancer and Prostatic Diseases. DOI: 10.1038/pcan.2016.25 |
0.355 |
|
| 2015 |
Gross ME. Blood-based gene expression profiling in castrate-resistant prostate cancer. Bmc Medicine. 13: 219. PMID 26365516 DOI: 10.1186/s12916-015-0463-8 |
0.313 |
|
| 2015 |
Dorff TB, Gross ME. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e270-3. PMID 25993185 DOI: 10.14694/EdBook_AM.2015.35.e270 |
0.301 |
|
| 2015 |
Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross ME, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. Plos One. 10: e0117758. PMID 25693195 DOI: 10.1371/Journal.Pone.0117758 |
0.411 |
|
| 2015 |
Ukimura O, Gross ME, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S, Kanazawa M, Aron M, Gill IS. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. The Prostate. 75: 863-71. PMID 25663102 DOI: 10.1002/pros.22969 |
0.343 |
|
| 2014 |
Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn DI, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 17: 359-65. PMID 25245366 DOI: 10.1038/Pcan.2014.37 |
0.329 |
|
| 2014 |
Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1335-44. PMID 24418642 DOI: 10.1158/1078-0432.CCR-13-2436 |
0.39 |
|
| 2013 |
Gross ME. Prostate cancer: Age is nothing but a number. Nature Reviews. Urology. 10: 683-4. PMID 24217679 DOI: 10.1038/nrurol.2013.265 |
0.369 |
|
| 2013 |
Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. The Prostate. 73: 306-15. PMID 22911164 DOI: 10.1002/Pros.22569 |
0.407 |
|
| 2012 |
Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. European Urology. 62: 55-63. PMID 22445223 DOI: 10.1016/j.eururo.2012.03.006 |
0.365 |
|
| 2012 |
Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross ME, Kuhn P. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Physical Biology. 9: 016002. PMID 22306736 DOI: 10.1088/1478-3975/9/1/016002 |
0.335 |
|
| 2011 |
Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant prostate cancer. The Oncologist. 16: 1349-58. PMID 21964003 DOI: 10.1634/theoncologist.2010-0014 |
0.348 |
|
| 2011 |
Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. The Lancet. Oncology. 12: 204-6. PMID 21310657 DOI: 10.1016/S1470-2045(11)70003-1 |
0.354 |
|
| 2011 |
Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs. 29: 1432-40. PMID 20336348 DOI: 10.1007/s10637-010-9420-8 |
0.382 |
|
| 2010 |
Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clinical Chemistry. 56: 1492-5. PMID 20581083 DOI: 10.1373/clinchem.2010.143297 |
0.334 |
|
| 2010 |
Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. The Prostate. 70: 1201-10. PMID 20564426 DOI: 10.1002/pros.21155 |
0.541 |
|
| 2009 |
Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, CalabrĂ² F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7421-8. PMID 19920114 DOI: 10.1158/1078-0432.Ccr-09-1691 |
0.304 |
|
| 2009 |
Gross M, Ramirez C, Luthringer D, Nepomuceno E, Vollmer R, Burchette J, Freedland SJ. Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. The Prostate. 69: 520-7. PMID 19107851 DOI: 10.1002/pros.20901 |
0.347 |
|
| 2007 |
Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. Bmc Cancer. 7: 142. PMID 17662137 DOI: 10.1186/1471-2407-7-142 |
0.387 |
|
| 2007 |
Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 110: 556-63. PMID 17577218 DOI: 10.1002/Cncr.22811 |
0.335 |
|
| 2007 |
Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1979-86. PMID 17404077 DOI: 10.1158/1078-0432.CCR-06-1156 |
0.437 |
|
| 2006 |
Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clinical Genitourinary Cancer. 4: 299-302. PMID 16729916 DOI: 10.3816/Cgc.2006.N.012 |
0.351 |
|
| 2006 |
Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. Bju International. 97: 691-7. PMID 16536755 DOI: 10.1111/j.1464-410X.2006.05974.x |
0.342 |
|
| 2004 |
Shazer RL, Luthringer D, Agus DB, Gross ME. Ductal adenocarcinoma of the prostate. Clinical Advances in Hematology & Oncology : H&O. 2: 393-5; discussion 39. PMID 16163211 |
0.387 |
|
| 2004 |
Gross ME, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 2: 53-6, 64. PMID 16163160 |
0.347 |
|
| 2004 |
Gross M, Yang R, Top I, Gasper C, Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene. 23: 3059-66. PMID 14981544 DOI: 10.1038/Sj.Onc.1207443 |
0.621 |
|
| 2001 |
Gross M, Liu B, Tan JA, French FS, Carey M, Shuai K. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells Oncogene. 20: 3880-3887. PMID 11439351 DOI: 10.1038/Sj.Onc.1204489 |
0.678 |
|
| 2001 |
Liu B, Gross M, Hoeve Jt, Shuai K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proceedings of the National Academy of Sciences of the United States of America. 98: 3203-3207. PMID 11248056 DOI: 10.1073/Pnas.051489598 |
0.594 |
|
| Show low-probability matches. |